Douglas Hunt
Net worth: 945 350 $ as of 30/05/2026
Net worth: 945 350 $ as of 30/05/2026
Mr. Douglas Hunt is a Chief Regulatory Affairs Officer at Puma Biotechnology, Inc. Mr. Hunt was previously employed as a VP-Regulatory Affairs & Quality Assurance by ArmaGen, Inc., a Vice President-Global Regulatory Affairs by Baxter Healthcare Corp., and an Executive Director-Therapeutic Area by Amgen, Inc. He received his undergraduate degree from the University of Portsmouth.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 12/04/2026 | 131,848 ( 0.26% ) | 945 350 $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | General Counsel | 31/12/2017 |
| Companies | Position | End |
|---|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | General Counsel | 30/11/2017 |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | General Counsel | 28/02/2015 |
| AMGEN INC. | Corporate Officer/Principal | 30/06/2008 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | Health Technology |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Select your edition
All financial news and data tailored to specific country editions